Login
$HTFL
$47.68 +$0.82 (1.75%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
John C.M. Farquhar Also a director
President, Chief Executive Officer & Director
54 Not stated Not stated $5,989,882
Vikram Verghese
Chief Financial Officer
42 Since 2023
3 years
2021 $2,357,900
Campbell D.K. Rogers
Chief Medical Officer
64 Since 2012
14 years
Not stated Not reported
Marie L. Jones
Chief Accounting Officer
Title from the Form 4 dated Sep 8, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
8.9 years
from year joined
CEO also chairs the board
No
William C. Weldon
Director Age On board Independent Committees Other public boards 2025 pay Source
William C. Weldon
77 2014
12 years
Independent
Nominating and Corporate Governance Committee · Chair
Fairfax Financial Holdings Limited $339,662
John C.M. Farquhar
54 2022
4 years
Not stated None stated None stated Paid as CEO
Julie A. Cullivan
60 2020
6 years
Independent
Audit Committee
Axon Enterprises, Inc. $292,955
Timothy C. Barabe
73 2022
4 years
Independent
Audit Committee · Chair
Cartesian Therapeutics, Inc. $294,433
Jeffrey C. Lightcap
67 2011
15 years
Independent
Compensation Committee
CareView Communications, Inc., RTI Surgical, Inc. $509,237
Wayne J. Riley, M.D.
67 2021
5 years
Independent
Compensation Committee · Chair
HCA Healthcare, Inc. $295,173
Casey M. Tansey
68 2010
16 years
Independent
Nominating and Corporate Governance Committee
Inspire Medical Systems, Inc., Shoulder Innovations, Inc. $509,237

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Hayfin HeartFlow UK Limited
$ 23,000,000.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
BCLS Fund III Investments, LP
$ 6,595,648.51

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
Lonnie M. Smith
$ 1,822,713.44

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
HCPCIV 1, LLC
$ 1,460,234.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
U.S. Venture Partners Funds
funds of which Casey M. Tansey, a director, is a controlling member; own more than 5% of our outstanding capital
$ 811,558.22

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
Vikram Verghese
$ 144,650.88

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy
Hayfin HeartFlow UK Limited
lender under the 2024 Credit Agreement; owns more than 5% of our outstanding capital
$23.0 million
2025

Converted $23.0 million of outstanding term loan indebtedness into 2025 Convertible Notes

With the Company Open in proxy
Hayfin HeartFlow UK Limited
lender under prior credit agreement; holder of warrants
Amount not stated

Company issued warrants to purchase 185,407 shares of common stock, later adjusted to additional warrants

With the Company Open in proxy
Hayfin HeartFlow UK Limited
lender under prior credit agreement; holder of warrants
Amount not stated
2025

Hayfin net exercised all outstanding common stock warrants for 1,646,317 shares of common stock

With the Company Open in proxy
BCLS Fund III Investments, LP
$ 99,999,998.18

Purchased 35,081,564 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy
The Lonnie and Cheryl Smith Family Trust
trust affiliated with Lonnie M. Smith, a director in 2025 prior to our initial public offering
$ 15,408,505.15

Purchased 8,068,125 shares of Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy
Hayfin HeartFlow UK Limited
$ 15,136,167.06

Purchased Series F and Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy
HCPCIV 1, LLC
$ 13,654,851.50

Purchased Series F and Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy
Wellington Entities
$ 11,885,000.12

Purchased 4,169,444 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy
U.S. Venture Partners Funds
funds of which Casey M. Tansey, a director, is a controlling member; own more than 5% of our outstanding capital
$ 9,999,998.68

Purchased 3,508,156 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy
Michael Smith
relative of Mr. Lonnie M. Smith, one of our directors in 2025 prior to our initial public offering
Did not exceed $325,000
2023, 2024, and 2025

Non-executive employee of the Company since 2014 with overall cash compensation not exceeding the stated amount for 2023, 2024 and 2025

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support